Advertisement

Topics

Polaryx Therapeutics Receives Orphan Drug Designation From The U.S. FDA For PLX-200 For Rare Pediatric Disease

20:00 EDT 6 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Polaryx Therapeutics Receives Orphan Drug Designation From The U.S. FDA For PLX-200 For Rare Pediatric Disease

NEXT ARTICLE

More From BioPortfolio on "Polaryx Therapeutics Receives Orphan Drug Designation From The U.S. FDA For PLX-200 For Rare Pediatric Disease"

Quick Search
Advertisement